| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | -27.54% | Goldman Sachs | $1.5 → $1 | Maintains | Sell |
| 05/15/2023 | — | Raymond James | Downgrades | Market Perform → Underperform | |
| 05/11/2023 | 8.7% | Goldman Sachs | $2 → $1.5 | Maintains | Sell |
| 03/03/2023 | 26.81% | Piper Sandler | $2.25 → $1.75 | Maintains | Underweight |
| 01/31/2023 | 44.93% | Goldman Sachs | → $2 | Downgrades | Neutral → Sell |
| 11/09/2022 | 117.39% | SVB Leerink | $2.5 → $3 | Maintains | Market Perform |
| 08/25/2022 | -27.54% | Credit Suisse | → $1 | Initiates Coverage On | → Underperform |
| 08/18/2022 | 63.04% | Piper Sandler | $2.5 → $2.25 | Maintains | Underweight |
| 08/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 08/10/2022 | 81.16% | SVB Leerink | $2 → $2.5 | Maintains | Market Perform |
| 07/26/2022 | 81.16% | Cowen & Co. | $8 → $2.5 | Downgrades | Outperform → Market Perform |
| 07/21/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 07/19/2022 | 479.71% | Cowen & Co. | $10 → $8 | Maintains | Outperform |
| 07/19/2022 | — | Benchmark | Downgrades | Buy → Hold | |
| 07/19/2022 | 44.93% | SVB Leerink | $8 → $2 | Downgrades | Outperform → Market Perform |
| 06/13/2022 | 334.78% | Benchmark | $13 → $6 | Maintains | Buy |
| 06/03/2022 | 81.16% | Piper Sandler | → $2.5 | Initiates Coverage On | → Underweight |
| 05/05/2022 | 515.94% | Raymond James | $10.5 → $8.5 | Maintains | Outperform |
| 05/04/2022 | 1131.88% | Morgan Stanley | $18 → $17 | Maintains | Equal-Weight |
| 04/19/2022 | 624.64% | Goldman Sachs | $14 → $10 | Maintains | Neutral |
| 04/18/2022 | 660.87% | Raymond James | $15 → $10.5 | Maintains | Outperform |
| 02/28/2022 | 986.96% | Raymond James | $36 → $15 | Maintains | Outperform |
| 02/25/2022 | 1711.59% | SVB Leerink | $30 → $25 | Maintains | Outperform |
| 02/15/2022 | 1204.35% | Morgan Stanley | $37 → $18 | Maintains | Equal-Weight |
| 11/09/2021 | 2508.7% | Raymond James | $38 → $36 | Maintains | Outperform |
| 08/05/2021 | 2798.55% | Morgan Stanley | $41 → $40 | Maintains | Equal-Weight |
| 08/04/2021 | 2436.23% | Benchmark | → $35 | Upgrades | Hold → Buy |
| 06/21/2021 | 2436.23% | Wells Fargo | $30 → $35 | Maintains | Equal-Weight |
| 06/15/2021 | 2581.16% | Raymond James | → $37 | Initiates Coverage On | → Outperform |
| 06/03/2021 | 2291.3% | Goldman Sachs | → $33 | Initiates Coverage On | → Neutral |
| 05/25/2021 | 2073.91% | Wells Fargo | → $30 | Initiates Coverage On | → Equal-Weight |
| 05/06/2021 | 2871.01% | Morgan Stanley | $45 → $41 | Maintains | Equal-Weight |
| 05/05/2021 | 3523.19% | SVB Leerink | $65 → $50 | Maintains | Outperform |
| 04/05/2021 | 3378.26% | Oppenheimer | → $48 | Upgrades | Perform → Outperform |
| 02/22/2021 | 3160.87% | Morgan Stanley | $41 → $45 | Maintains | Equal-Weight |
| 02/19/2021 | 3160.87% | Morgan Stanley | $41 → $45 | Maintains | Equal-Weight |
| 02/18/2021 | 4102.9% | Ladenburg Thalmann | $46.5 → $58 | Upgrades | Neutral → Buy |
| 02/18/2021 | 4610.14% | SVB Leerink | $64 → $65 | Maintains | Outperform |
| 02/01/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 01/20/2021 | 4537.68% | SVB Leerink | $48 → $64 | Maintains | Outperform |
| 11/06/2020 | 2871.01% | Morgan Stanley | $38 → $41 | Maintains | Equal-Weight |
| 11/06/2020 | 3378.26% | SVB Leerink | $44 → $48 | Maintains | Outperform |
| 11/03/2020 | 3088.41% | SVB Leerink | $34 → $44 | Maintains | Outperform |
| 10/14/2020 | 3160.87% | JP Morgan | → $45 | Downgrades | Overweight → Neutral |
| 09/09/2020 | 2653.62% | Morgan Stanley | → $38 | Initiates Coverage On | → Equal-Weight |
| 08/05/2020 | 2363.77% | SVB Leerink | $40 → $34 | Maintains | Outperform |
| 07/15/2020 | 2798.55% | SVB Leerink | $25 → $40 | Maintains | Outperform |
| 07/01/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/06/2020 | 1711.59% | SVB Leerink | $20 → $25 | Maintains | Outperform |
| 04/08/2020 | 1349.28% | Benchmark | $31 → $20 | Maintains | Buy |
| 03/04/2019 | — | Chardan Capital | Initiates Coverage On | → Buy |
What is the target price for Invitae (NVTA)?
The latest price target for Invitae (NYSE: NVTA) was reported by Goldman Sachs on July 21, 2023. The analyst firm set a price target for $1.00 expecting NVTA to fall to within 12 months (a possible -27.54% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Invitae (NVTA)?
The latest analyst rating for Invitae (NYSE: NVTA) was provided by Goldman Sachs, and Invitae maintained their sell rating.
When is the next analyst rating going to be posted or updated for Invitae (NVTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Invitae, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Invitae was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
Is the Analyst Rating Invitae (NVTA) correct?
While ratings are subjective and will change, the latest Invitae (NVTA) rating was a maintained with a price target of $1.50 to $1.00. The current price Invitae (NVTA) is trading at is $1.38, which is out of the analyst's predicted range.